

20<sup>th</sup> December, 2021

To,  
Department of Corporate Services

To,  
Corporate Listing Department

**BSE Limited**  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001  
Scrip Code: **BSE – 524500**

**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051  
Scrip Code: **NSE – KILITCH**

Respected Sir/Madam,

**Sub: Outcome of Board Meeting held on December 20, 2021 and Compliance of Regulations 29 and 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to above subject matter, we wish to inform you that the Board of Directors at their meeting held on December 20, 2021 at 03:00 P.M. have inter-alia approved the following:

1. To issue equity shares and/or warrants convertible into equity shares on preferential basis at Rs. 177.15/- to the following Promoters to meet the long term working capital requirements, general corporate purpose and such other purpose as the Board may decide.

Sr. No.	Name	Warrants (No)	Category
1.	Mr. Mukund Mehta	2,50,000	Promoter
2.	Mr. Bhavin Mehta	2,50,000	Promoter

The issue price has been determined in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

\* Note: Every warrant is entitled to receive 1 equity share at the time of conversion.

2. Convening Extra-Ordinary General Meeting of the members of the Company on Wednesday, 19<sup>th</sup> January, 2022 at 01:00 P.M. through Video Conference (“VC”)/ Other Audio Visual Means (“OAVM”) (“hereinafter referred to as “electronic mode”).

The meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 04:40 P.M.

We request you to take note of the same.

Thanking You,

Yours faithfully,

For **Kilitch Drugs (India) Limited**



**Mukund Mehta**  
(Managing Director)  
DIN:9C147876

